Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism

Nappi, Carmine; Farace, M. J.; Leone, Florencia González; Minutolo, Maria; Tommaselli, A; Montemagno, U

doi:10.1016/0028-2243(87)90101-8

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OCP therapy is recommended for 1–2 years and studies have demonstrated that suppression of serum androgens can continue for up to 2 years after discontinuation of OCPs [112] (however, another study caused controversy by demonstrating that serum androgens returned to baseline results after 3 months of discontinued therapy [113]). Potential side effects include alterations in insulin action, vascular reactivity and hypercoagulativity.…”

Section: Treatmentmentioning

confidence: 99%

Interventional Studies for Polycystic Ovarian Syndrome in Children and Adolescents

Vuguin

2010

Pediatric Health

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is characterized by chronic anovulation, clinical and/or biochemical hyperandrogenism, which can be associated with altered insulin action. Symptoms usually begin around menarche, but onset after puberty may also occur as a result of environmental modifiers such as weight gain. The consequences of PCOS extend beyond the reproductive axis; there is a substantial risk for development of metabolic and cardiovascular abnormalities similar to the metabolic syndrome. Currently, the treatment is targeted to the patient’s primary complaint such as hirsutism, restoration of regular menses or pregnancy. Pharmacological agents available for the treatment of hirsutism include androgen suppressors and peripheral androgen blockers. Recently, our understanding of the role of insulin resistance has led to the use of insulin-sensitizing medications as first-choice therapy. In conjunction with weight reduction and exercise, a pharmacologic reduction in insulin levels by either metformin or thiazolidinediones ameliorates both hyperinsulinemia and hyperandrogenism.

show abstract

Section: Treatmentmentioning

confidence: 99%